

Drug Utilization Review (DUR) Meeting Minutes September 9, 2013

Members Present: Norman Byers, John Savageau, Cheryl Huber, Greg Pfister, Jeffrey Hostetter, Peter Woodrow, Carlotta McCleary, Carrie Sorenson, Russ Sobotta

Members Absent: Todd Twogood, Leann Ness, Tanya Schmidt, Steve Irsfeld, James Carlson, Michael Booth

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair G. Pfister called the meeting to order at 1:00 pm. Chair G. Pfister asked for a motion to approve the minutes from the June meeting. N. Byers moved that the minutes be approved, and G. Betting seconded the motion. Chair G. Pfister called for a voice vote to approve the minutes. The motion passed with no audible dissent. New board member, Peter Woodrow was introduced to the Board.

Budget Update

B. Joyce informed the board members that for the 2011-2013 biennium, the net spend was 37.8 million dollars; 72.9 million dollars spend pre-rebate. There was approximately 35 million collected in rebates. This includes approximately 64,000 recipients and 1.43 million pharmacy claims.

Rayos Second Review

A motion and second were made at the June meeting to place Rayos on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Diclegis Second Review

A motion and second were made at the June meeting to place Diclegis on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Sitavig Second Review

A motion and second were made at the June meeting to place Sitavig on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent. This will be added to the Orally Disintegrating Tablets PA form.

Onmel Second Review

A motion and second were made at the June meeting to place Onmel on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Giazo Second Review

A motion and second were made at the June meeting to place Giazo on prior authorization. The topic was brought up for a second review. There was no public comment. After discussion, Chair G. Pfister called for a voice vote to approve the motion. The motion passed with no audible dissent.

Sirturo Review

B. Joyce reviewed Sirturo clinical information with the board. There was no public comment. J. Hostetter made a motion to make Sirturo unavailable in the retail setting. C. Huber seconded the motion. This topic will be brought up at the next meeting for finalization.

Brisdelle Review

B. Joyce reviewed Brisdelle clinical information with the board. There was no public comment. N. Byers made a motion to place Brisdelle on prior authorization. P. Woodrow seconded the motion. This topic will be brought up at the next meeting for finalization.

Vecamyl Review

B. Joyce reviewed Vecamyl clinical information with the board. There was no public comment. J. Hostetter made a motion to review more information at the December meeting. G. Pfister seconded the motion. This topic will be reviewed at the next meeting.

Nitroglycerin Lingual Spray/Sublingual Tablet Review

B. Joyce reviewed nitroglycerin spray/sublingual tablet clinical information with the board. There was no public comment. P. Woodrow made a motion to place Nitroglycerin Lingual Spray on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

COPD Review

B. Joyce reviewed agents used to treat COPD clinical information with the board. There was no public comment. J. Savageau made a motion to place agents used to treat COPD on prior authorization. P. Woodrow seconded the motion. This topic will be brought up at the next meeting for finalization.

Epinephrine Auto-Injections Review

B. Joyce reviewed epinephrine auto-injections clinical information with the board. R. Sobotta, representing Sanofi, spoke regarding Auvi Q. N. Byers made a motion to place epinephrine auto-injectors on prior authorization. G. Pfister seconded the motion. The department will review post rebate data to determine which drug is the best option (EpiPen or Auvi Q). This topic will be brought up at the next meeting for finalization.

Pulmozyme Review

B. Joyce reviewed Pulmozyme clinical information with the board. D. Evans, representing Genentech, spoke regarding Pulmozyme. J. Hostetter made a motion to place Pulmozyme on prior authorization. J. Savageau seconded the motion. This topic will be brought up at the next meeting for finalization.

Statin Review

B. Joyce reviewed statin information with the board. This topic was tabled until the next meeting.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. C. Huber moved to approve the new criteria and N. Byers seconded the motion. Chair G. Pfister called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held December 3, in Bismarck. C. Huber made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. G. Pfister adjourned the meeting.